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The marked induction of glial fibrillary acidic protein (GFAP) has been observed in astrocytes during neuropathological processes
accompanying reactive gliosis; however, the precise molecular mechanism(s) underlying this GFAP induction remains poorly resolved. Therefore,
in this study, we examined whether the change of nuclear factor-kappa B (NF-κB) activity can influence GFAP expression levels. Aspirin, widely
used to prevent NF-κB activity, reduced the levels of GFAP mRNA and protein in human astroglial cells including human glioblastoma A172 cells
and primary human brain astrocyte cells (HBAs). Furthermore, aspirin inhibited the effects of hypoxic injury on the up-regulation of GFAP
expression in HBAs. We confirmed the repressive effect of aspirin on GFAP transcription by GFAP promoter-driven reporter assay and found that
one NF-κB binding site conserved in the mouse and human GFAP gene promoters is critical for this effect. To further delineate whether NF-κB is
directly involved in the regulation of GFAP gene expression, we transfected A172 cells with an expression vector encoding a super-repressor
IκBα protein (IκBα-SR) to specifically inhibit NF-κB activity and found the marked reduction of GFAP protein levels in IκBα-SR-transfectant
cells. Taken together, our results suggest that NF-κB may play pivotal roles in GFAP gene expression.
© 2006 Elsevier B.V. All rights reserved.Keywords: GFAP; NF-κB; Aspirin; A172; HBAs; Hypoxia; Reactive gliosis1. Introduction
GFAP is an intermediate filament protein mainly expressed
in astrocytes for which it constitutes a selective marker [1].
Aside from its role as an astroglial lineage marker, the specific
expression of GFAP in astrocytes suggests that it plays an
important role in the function of these cells in central nervous
system (CNS). The functional implications of GFAP have been
obtained from studies of genetically engineered mice. Although
the absence of GFAP has relatively subtle effects on⁎ Corresponding author. Tel.: +82 51 240 7960; fax: +82 51 248 1023.
E-mail address: skbae@pusan.ac.kr (S.-K. Bae).
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doi:10.1016/j.bbamcr.2006.01.005development of GFAP null mice, studies on mice deficient in
GFAP and vimentin (GFAP−/−Vim−/−) suggested that the
upregulation of astrocytic intermediate filaments is a crucial
step in reactive gliosis [2–5]. Furthermore, GFAP transgenic
mice that constitutively overexpress GFAP showed chronic
reactive gliosis, which accompany the marked formation of
Rosenthal fibres in brain [6], the hallmark feature of the
devastating neurodegenerative disorder, Alexander disease [7].
Subsequent studies on Alexander disease patients demonstrated
that a gain of function of GFAP is the cause of most cases of this
disease [8]. Besides being a genetic cause of Alexander disease,
the abnormal induction of GFAP gene is closely related to
reactive gliosis along with astrocyte hypertrophy [9,10]. Despite
of its beneficial and neuroprotective role in early phases after
CNS injury, reactive gliosis is considered as inhibitor of CNS
283M.-K. Bae et al. / Biochimica et Biophysica Acta 1763 (2006) 282–289regeneration because of scar formation caused by strong GFAP-
positive reactive astrocytes, which prevents making normal
neuronal circuits [11].
It has been reported that brain ischemia triggers a severe
reactive gliosis [12]. Progressive reactive gliosis also occurs in
an aging CNS, indicating that age-related reactive gliosis might
be one of factors that restrict neurogenesis in old individuals
[13,14]. Furthermore, one of the pathophysiological features of
Alzheimer's disease is reactive gliosis around senile plaques
[15]. Therefore, attempts to identify and characterize factors
regulating GFAP gene expression have been a way to learn about
the molecular mechanisms of a variety of neuropathological
conditions that are closely associated with GFAP upregulation
and thereby with reactive gliosis, and to facilitate development
of strategies to minimize these devastating processes.
So far, several factors have been reported to contribute to
GFAP induction. For example, astrocyte-inducing cytokines,
leukemia inhibitory factor (LIF) and bone morphogenetic
protein (BMP) 2 have been shown to induce GFAP gene
expression via STAT3/p300/Smad1 complex [16]. In addition,
bFGF, CNTF, IL-1, IL-6, TGF-β1, and TNF-α have been
proposed as potential modulators of GFAP expression as well as
mediators of reactive gliosis [17–22]. However, in this case,
little has been reported about intracellular transcription factor
(s), which transduce those extracellular signals to induce GFAP
gene expression.
The transcription factor NF-κB plays an important role not
only in the development of many tumors but also in the
pathogenesis of chronic neurological diseases characterized by
inflammation [23]. Recent studies showed that an activated NF-
κB is detected in both astrogliogenesis [24] and reactive gliosis
[25], and both processes are concomitant with GFAP induction
[1]. Furthermore, NF-κB is activated by the extrinsic GFAP-
regulatory factors mentioned above [26–30]. These observa-
tions raise the possibility that NF-κB may be involved in the
regulation of GFAP gene expression.
Interestingly, we have found one conserved NF-κB binding
site in the mouse and human GFAP gene promoter. Therefore,
the present study was undertaken to examine the role of NF-κB
as a GFAP gene regulator in human astroglial cells.
2. Materials and methods
2.1. Reagents and antibodies
Aspirin was purchased from Sigma. Rabbit polyclonal anti-human GFAP
and mouse monoclonal anti-human GFAP antibodies were from Dako Ltd. and
Sigma, respectively. Mouse monoclonal anti-chick α-Tubulin and rabbit
polyclonal anti-human IκBα antibodies were from Santa Cruz Biotechnology.
Alexa 488-conjugated goat anti-rabbit IgG and Alexa 594-conjugated goat anti-
mouse IgG were purchased from Molecular Probes, Inc.
2.2. Plasmids
An NF-κB-dependent luciferase reporter construct that consists of three
synthetic copies of the NF-κB-consensus sequence from the Ig-κ chain promoter
upstream of the luciferase gene and a super-repressor IκBα (IκBα-SR) plasmid
were kindly provided by Dr. Ronald T. Hay [26]. A mouse GFAP promoter
(2.5 kb)-containing luciferase reporter construct, GF1L, was obtained from Dr.
Tetsuya Taga and Dr. Kazuhiro Ikenaka [31].2.3. Cell culture
Since human glioblastoma A172 cells express high levels of GFAP protein
in their cytoplasm [32], they may provide a good model to investigate signals
that reduce GFAP expression levels. A172 cells (ATCC #CRL-1620, American
Type Culture Collection, VA) were grown in growth medium (i.e., Dulbecco's
Modified Eagle Medium (DMEM, GibcoBRL) supplemented with 10% (v/v)
heat-inactivated FBS (GibcoBRL) and 1% (v/v) penicillin-streptomycin at 37 °C
in a humidified incubator with 5% CO2 in 95% air. Primary human brain
astrocyte cells (HBAs) were purchased from Applied Cell Biology Research
Institute (#ACBRI 371) and grown in DMEM containing 10% FBS (GibcoBRL)
and antibiotic/antimicotic mixture (100 μ/ml penicillin G, 100 μg/ml
streptomycin and 0.25 μg/ml amphotericin B) (Gibco BRL) in an atmosphere
of 5% CO2/95% air at 37 °C. Passages 7–9 of HBAs were used in this study.
2.4. In vitro hypoxia
HBAs were grown to 90–95% confluence in complete growth medium. For
the experiments, media were removed and cells washed in PBS. Growth
medium with or without aspirin was then added to the cells and they were
subjected to a severe hypoxia (1% oxygen) for the indicated times in an
anaerobic chamber (Anaerobic SystemModel 1024, Forma Scientific) equipped
with a humidified, temperature-controlled incubator directly accessible within
the chamber. The entire system was purged with 95% N2/5% CO2 atmosphere.
We have confirmed that these conditions do not affect viability of astrocyte
cultures (data not shown).
2.5. Western immunoblot analysis
Harvested cells were lysed in a lysis buffer (0.1% SDS, 1.0% Triton X-100
and 1.0% Deoxycholate in PBS containing 1 mM DTT, 1% protease inhibitor
cocktail (Sigma), 1 mM PMSF, 1 mM Na3VO4, 1 mM NaF and 1 mM β-
glycerophosphate) and protein concentration was measured with BCA assay. A
constant protein concentration (30 μg/lane) was used. The protein extracts were
boiled for 5 min, loaded, separated by SDS-PAGE and transferred to
nitrocelluloses membranes. The membranes were then probed with appropriate
antibodies. The signal was developed with the enhanced chemiluminescence
(ECL) detection system (Amersham-Pharmacia Biotech.).
2.6. Immunocytochemistry
A172 cells cultured on a coverglass were fixed in 4% paraformaldehyde (in
phosphate-buffered saline) for 15 min, blocked with 0.3% Triton X-100/10%
normal goat serum/PBS for 30 min, and then labeled with appropriate primary
antibodies. After overnight incubation at 4 °C, the cells were washed with cold-
PBS three times and incubated with Alexa 488- or Alexa 594- conjugated
secondary antibodies for 1 h at RT. Coverslips were mounted in Vectastain
containing DAPI (Vector Laboratories). Cells were analyzed using fluorescent
microscopy.
2.7. RT-PCR
The mRNA levels of GFAP gene were analyzed by RT-PCR. First-strand
cDNA synthesis was carried out on 3 μg of total RNAwith a reverse transcription
kit (Invitrogen). One tenth of the reaction mixture was used as template for PCR
amplification. Primers for humanGFAP (hGFAP) and humanβ-actin for internal
control are hGFAP, 5′-CTGTTGCCAGAGATGGAGGTT-3′ and 5′-TCATCG-
CTCAGGAGGTCCTT-3′; andβ-actin, 5′-GACTACCTCATGAAGATC-3′ and
5′-GATCCACATCTGCTGGAA-3′. RT-PCR products of GFAP and β-actin
were 382 bp and 507 bp, respectively. The amplification profile for GFAP was
94 °C for 30 s, 53 °C for 30 s, and 72 °C for 30 s for 30 cycles.
2.8. Site-directed mutagenesis
The NF-κB binding site (GGGGCTGCCC) of GF1L was targeted for
mutagenesis. The mutation was made with a QuikChange site-directed
mutagenesis kit (Stratagene). Oligonucleotide primer pair used for the mutation
Fig. 1. Aspirin reduces GFAP protein levels in A172 cells. (A) Western
immunoblot analysis using rabbit polyclonal anti-human GFAP antibody was
performed on total protein extracts from A172 cells treated with 0 to 5 mM
aspirin for 3 days. α-Tubulin was used as a control protein. (B) Relative GFAP
protein levels normalized with α-Tubulin protein. The density of each band in
each lane from three independent experiments was quantified by scanning
densitometry and then expressed as mean±S.D. (C) Photographs showing
indirect immunofluorescence analysis of A172 cells either untreated (0) or
treated with 5 mM aspirin for 3 days, then immunocytochemically stained with
rabbit polyclonal anti-human GFAP antibody. The signal was detected using
Alexa 488-conjugated goat anti-rabbit IgG (green). Nuclei were stained with
DAPI (blue). (For interpretation of the references to colour in this figure legend,
the reader is referred to the web version of this article.)
Fig. 2. Aspirin reduces GFAP mRNA levels and represses transcriptional
activity of GFAP promoter in A172 cells. (A) RT-PCR analysis showing
mRNA levels of GFAP in A172 cells treated with 0 to 5 mM aspirin for 2
days. (B) Relative GFAP mRNA levels normalized with β-actin mRNA. The
density of each band in each lane from three independent experiments was
quantified by scanning densitometry and then expressed as mean±S.D. (C)
A172 cells were transfected with GFAP promoter-luciferase reporter
constructs. Twenty-four hours after transfection, cells were either unstimulated
or stimulated with aspirin for a further 24 h. Results were normalized using β-
galactosidase activity and expressed as a percentage of the GF1L-transfectant
without treatment with aspirin. Data are the mean±S.D. from three
independent experiments.
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GCAGCCCACTTTGCTGCCCTTGCCATATG and CATATGGCAAGGG-
CAGCAAAGTGGGCTGC. Direct DNA sequencing was performed to confirm
all engineered mutations.
2.9. Transient transfection and luciferase assay
A172 cells were plated on 24-well plates (Nunc) and transfected the next day
with either mouse GFAP promoter-luciferase constructs (GF1L or GF1L-
NBSPM) or a NF-κB-dependent luciferase construct. Control transfections were
made using a lacZ gene that is driven by an RSV promoter. Transfections wereperformed using Lipofectamin (Invitrogen) according to the manufacturer's
instructions. Twenty-four hours after transfection, the cells were treated with
aspirin for 24 h and then solubilized. Luciferase activity was measured by using
a luminometer (Turner Designs, Inc.) and β-galactosidase activity was measured
by using the Galactolight kit (Promega) as recommended by the manufacturer.
The relative level of promoter activation in each experiment was calculated by
dividing the luciferase activity by β-galactosidase activity. The mutated super-
repressor IκBα expression plasmid was also used for transient transfection.
After 40 h of transfection, transfected A172 cells were either lysed for Western
immunoblot analysis or fixed for the immunocytochemical staining with mouse
monoclonal anti-human GFAP antibody and rabbit polyclonal anti-human IκBα
antibody as specified above.
Fig. 3. Aspirin reduces IκBα protein levels and represses NF-κB-driven
transcription in A172 cells. (A) Western immunoblot analysis using rabbit
polyclonal anti-human IκBα was performed on total protein extracts from A172
cells treated with 0 to 5 mM aspirin for 3 days. α-Tubulin was chosen as a control
protein. (B) A172 cells were transfected with NF-κB-dependent luciferase
reporter construct. After 24 h of transfection, cells were either unstimulated or
stimulated with aspirin for a further 24 h. Results shown were normalized using
β-galactosidase activity. Data are the mean±S.D., expressed as a percentage of
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3.1. Aspirin reduces GFAP protein levels in A172 cells
Initial experiments were performed to examine the effects of
aspirin on cell viability. Using the MTT assay (data not shown),
we chose noncytotoxic doses of aspirin, 2 and 5 mM, for the
following studies. To analyze whether aspirin could affect
GFAP protein levels, Western immunoblot analysis was per-
formed. As shown in Fig. 1A and B, aspirin down-regulated
GFAP protein levels in A172 cells by ∼20% over basal levels.
Levels of control protein (α-Tubulin) were unaffected by
aspirin. The reduction in GFAP levels by aspirin treatment was
confirmed by immunocytochemistry. As shown in Fig. 1C, a
strong, cytoplasmic staining of GFAP protein was observed in
A172 cells, which is consistent with previous data [32], whereas
the treatment of cells with 5 mM aspirin significantly reduced
GFAP protein levels. These results indicated that aspirin has
inhibitory effects on GFAP protein levels.
3.2. Aspirin represses GFAP gene transcription by blocking
NF-κB pathway in A172 cells
To investigate whether aspirin affects GFAP mRNA levels,
we performed RT-PCR analysis. As shown in Fig. 2A and B, a
dramatic decrease (∼22%) in the levels of GFAP mRNAFig. 4. Inhibition of NF-κB reduces GFAP protein levels in A172 cells. A172 cells were transfected with either pcDNA3 or pcDNA3-IκBα-SR expression plasmids.
Forty hours after transfection, cells were either lysed for Western immunoblot analysis using mouse monoclonal anti-human GFAP, rabbit polyclonal anti-human
IκBα, or mouse monoclonal anti-chick α-Tubulin antibodies (A), or fixed for immunocytochemical analysis as specified below (B). Photographs showing
immunocytochemically stained cells with both rabbit polyclonal anti-human IκBα and mouse monoclonal anti-human GFAP antibodies. The signals were detected
using fluorescein-conjugated secondary antibodies, Alexa 488-conjugated goat anti-rabbit IgG and Alexa 594-conjugated goat anti-mouse IgG. Nuclei were stained
with DAPI (blue). Arrow indicates A172 cells overexpressing superrepressor IκBα (green), in which only very weak GFAP signals (red) can be detected, whereas
control A172 cells indicated by arrowhead show strong GFAP-positive signals (red). (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
the control without treatment with aspirin, from three independent experiments.
Fig. 5. Aspirin reduces the levels of GFAP mRNA and protein in HBAs. (A) RT-
PCR analysis showing mRNA levels of GFAP in HBAs treated with 0 to 5 mM
aspirin for 2 days. (B) Relative GFAP mRNA levels normalized with β-actin
mRNA. The density of each band in each lane from three independent
experiments was quantified by scanning densitometry and then expressed as
mean±S.D. (C) Western immunoblot analysis using rabbit polyclonal anti-
human GFAP antibody was performed on total protein extracts from HBAs
treated with 0 to 5 mM aspirin for 2 days. α-Tubulin was used as a control
protein. (D) Relative GFAP protein levels normalized with α-Tubulin protein.
Statistical analysis of densitometric readings from three separate Western blot
analysis. Data are expressed as mean±S.D. HBAs, primary human brain
astrocyte cells.
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aspirin may affect the transcription of GFAP gene.
To confirm the notion, we examined the activity of GFAP
promoter in aspirin-treated A172 cells using the transient
expression system. We used the mouse GFAP promoter in this
study since GFAP promoter sequences are highly conserved
between the mouse and human GFAP gene as described below.
As shown in Fig. 2C, aspirin decreased the basal transcription
level driven by the GFAP promoter (GF1L) by ∼29%. To
delineate the molecular mechanisms of aspirin-mediated
inhibitory effects on GFAP gene transcription, we compared
the 5′-upstream promoter sequence between the mouse and
human GFAP gene and found a completely conserved NF-κB
binding site, GGGGCTGCCC (−1449 to −1440 in mouse;
−1414 to −1405 in human) (data not shown). This finding
suggests that GFAP gene expression may be under the direct
control of NF-κB and that the reduced levels of GFAP mRNA
and protein in aspirin-treated A172 cells are possibly due to the
inhibitory effects of aspirin on NF-κB activity. To examine NF-
κB-dependence for a GFAP reporter system, we introduced
nucleic acid substitutions in the NF-κB binding site
(TTTGCTGCCC; GF1L-NBSPM) of GF1L. As shown in Fig.
2C, this mutation abolished the inhibitory effects of aspirin on
GFAP promoter. Furthermore, basal activity of GF1L-NBSPM
was much reduced from basal GF1L activity and comparable to
the GF1L activity observed in 5 mM aspirin-treated A172 cells.
These results indicated that aspirin has inhibitory effects on
GFAP gene transcription, which is mediated by repressing NF-
κB activity.
3.3. Aspirin reduces IκBα protein levels and represses NF-κB
-driven transcription in A172 cells
Aspirin has been known to regulate NF-κB activity by either
increasing [33] or decreasing cytoplasmic IκBα protein levels
[34]. To evaluate the effect of aspirin on the IκBα protein levels
in A172 cells, Western immunoblot analysis was performed. As
shown in Fig. 3A, the protein levels of IκBα were decreased in
A172 cells treated with aspirin. Since the IκBα protein levels
were unexpectedly reduced in response to aspirin, we next
examined the effect of aspirin on NF-κB transcriptional activity
in A172 cells by transfecting with NF-κB-dependent luciferase
reporter construct. As shown in Fig. 3B, a dose-dependent
reduction in NF-κB-driven luciferase expression was observed
in aspirin-treated A172 cells compared to untreated A172 cells.
These results suggested that in A172 cells, aspirin represses a
constitutive NF-κB activity via a novel mechanism not by
simply stabilizing IκBα protein levels in the cytoplasm.
3.4. Inhibition of NF-κB activity via IκBα-SR reduces GFAP
protein levels in A172 cells
To demonstrate the direct involvement of NF-κB in
regulating GFAP gene expression, we used IκBα-SR expres-
sion system to specifically prevent NF-κB activity [26]. A172
cells were transfected with a plasmid to overexpress a
superrepressor form of the NF-κB inhibitor, IκBα-SR. Westernimmunoblot analysis showed that the GFAP protein levels were
highly reduced in IκBα-SR-transfectant cells (Fig. 4A). The
findings from Western immunoblot analysis were further
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the GFAP signal was very weak in IκBα-SR-transfectant cells
compared to the untransfected cells. These results strongly
suggested that NF-κB could directly regulate GFAP gene
expression.
3.5. Aspirin reduces GFAP mRNA and protein levels in HBAs
To investigate whether the results obtained from the A172
cell line reflect the situation in primary astrocyte cells, we
cultured primary human brain astrocyte cells (HBAs). As
shown in Fig. 5A and B, aspirin decreased the levels of GFAP
mRNA in a dose-dependent manner by ∼24%. The levels of
GFAP protein was also declined by ∼20% under the treatment
of aspirin (Fig. 5C and D). These results indicated that aspirin
could repress GFAP gene expression in primary astrocyte cells.
Although the most distinct inhibition of GFAP gene expression
was observed in cultures treated with 5 mM of aspirin (Fig. 5A–
D), we used aspirin concentration of 3.5 mM instead of 5 mM in
the following studies because of cellular toxicity at 5 mM of
aspirin (data not shown).
3.6. Aspirin restrains hypoxia-induced up-regulation of GFAP
mRNA and protein levels in HBAs
In order to test whether the observed responses were specific
to the basal GFAP expression or not, we next investigated the
influence of aspirin on GFAP up-regulation induced by
hypoxia. It has been reported that brain ischemia/hypoxia
induces astrogliosis and GFAP level is significantly higher in
the ipsilateral hypoxia/ischemia cortex compared to sham
cortex [12]. To examine whether this in vivo induction of
GFAP expression by hypoxia could be reproducible in an in
vitro system, HBAs were treated with hypoxia and analyzed the
GFAP mRNA levels. After exposure to 1% O2 for 24 h, the
levels of GFAP mRNA were markedly increased by ∼3.5-fold
over the normoxic control (Fig. 6A and B). To confirm the
effect of hypoxia on its target genes, the expression of vascular
endothelial growth factor (VEGF), a well-known hypoxia-
inducible gene, was also examined. As shown in Fig. 6A,
hypoxic treatment increased the levels of VEGF mRNA by
∼2.5-fold. Next, we examined the effect of aspirin on hypoxia-
induced up-regulation of GFAP gene expression and found that
aspirin prevented the hypoxic induction of GFAP expression in
the levels of both mRNA (Fig. 6C) and protein (Fig. 6D and E).Fig. 6. Aspirin restrains hypoxia-induced up-regulation of GFAP mRNA and
protein levels in HBAs. (A) RT-PCR analysis showing mRNA levels of GFAP or
VEGF in HBAs in response to hypoxia. (B) Relative GFAP mRNA levels
normalized with β-actin mRNA. The density of each band in each lane was
quantified by scanning densitometry and then expressed as mean±S.D. (C) RT-
PCR analysis showing mRNA levels of GFAP in HBAs treated with 0 to
3.5 mM aspirin for 2 days under the normoxic (N)- or hypoxic (H)-conditions.
(D) Western immunoblot analysis showing protein levels of GFAP in HBAs
treated with 0 to 3.5 mM aspirin for 2 days under the normoxic (N)- or hypoxic
(H)-conditions. (E) Relative GFAP protein levels normalized with α-Tubulin
protein. Statistical analysis of densitometric readings from three separate
Western immunoblot analysis. Data are expressed as mean±S.D.These results suggest that aspirin has inhibitory effects on
hypoxia-induced GFAP up-regulation as well as on basal GFAP
expression.
4. Discussion
GFAP, the earliest hallmark of reactive gliosis [1], is
extensively synthesized in astrocytes within and adjacent to
the site of brain injury and contributes to the rapid formation of
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regeneration [11,12]. Previous reports showed that the inhibi-
tion of GFAP expression with antisense GFAP mRNA not only
blocked astrogliosis but also relieved the blockade of neurite
outgrowth [35].
In this study, we found that aspirin has inhibitory effects on
basal GFAP mRNA and protein expression not only in A172
cells (Figs. 1 and 2) but also in HBAs (Fig. 5). We also showed
that aspirin inhibits the effect of hypoxia on GFAP up-
regulation in HBAs (Fig. 6). Furthermore, we showed that the
NF-κB, as a major target of aspirin, is directly involved in the
regulation of GFAP expression (Figs. 2C, 3B and 4). Therefore,
the inhibitory effect of aspirin on GFAP expression might make
aspirin or NF-κB-targeted drug(s) a potential therapeutic drug
against a variety of neuropathological conditions such as
neurodegeneration [15] and brain ischemia [12], which are
accompanied with reactive gliosis associated with a dramatic
induction of GFAP synthesis. In fact, recent reports showed that
reduced AD risk associates with long-term use of nonsteroidal
anti-inflammatory drugs (NSAIDs) [36,37]. Although NSAIDs
may function to alleviate the initiation of chronic AD
inflammation, the reduced risk for AD associated with
prolonged use of NSAIDs such as aspirin may also be, at
least in part, due to NSAIDs-mediated reduction in GFAP
synthesis and, ultimately, in the incidence of reactive gliosis.
Furthermore, considering that Alexander disease is caused by a
gain of function of GFAP [6–8], it would be interesting to
investigate therapeutic effects of aspirin on this disease using
animal models, for example, GFAP transgenic mice showing
the formation of Rosenthal fibres in their brains [6].
The mutant IκBα-SR has been used in many studies to
specifically prevent NF-κB activity. This IκBα-SR protein
associates normally with NF-κB, but carries serine-to-alanine
mutations at residues 32 and 36 that prevent proteosome-
mediated degradation, thereby preventing release and translo-
cation of NF-κB to the nucleus [26]. In the present study, under
the condition of IκBα-SR overexpression, GFAP protein levels
were significantly reduced (Fig. 4), confirming GFAP gene as a
downstream target gene of NF-κB transcription factor.
Although it has been well known that aspirin inhibits NF-κB
activity by inhibiting IkappaB kinase (IKK) activity and thereby
blocking IκBα degradation in the cytoplasm [33], recent report
suggested a different mechanism that aspirin represses NF-κB
activity by restricting the localization of NF-κB from the
nucleus to the nucleolus instead of stabilizing IκBα protein
levels [34]. In A172 cells treated with aspirin, IκBα protein
levels were not stabilized but decreased (Fig. 3A), and a strong
reduction of NF-κB activity was observed (Fig. 3B), suggesting
that the latter mechanism may be involved in aspirin-mediated
NF-κB inhibition, although the accumulation of NF-κB in the
nucleolus has not been investigated yet. While the nucleolar
sequestration of RelA (p65) following the reduction in IκBα
levels results in a decrease in NF-κB-driven transcription of
antiapoptic genes and, consequently, apoptosis of cololectal
cancer (CRC) cells [34], we did not observe any apoptotic
response to aspirin in A172 cells under the condition used in
this study (up to 5 mM aspirin for 3 days of treatment; data notshown). However, apoptosis would be induced in A172 cells if
either treated with aspirin at a concentration higher than 5 mM
or incubated for a longer time than 3 days.
Since A172 cell line is a transformed one, it seems to be an
artificial system for studying the regulatory mechanism of basal
GFAP expression. However, we reproduced inhibitory effects
of aspirin on basal GFAP expression in HBAs (Fig. 5).
Therefore, these data appear to support our hypothesis that
regulatory system of basal GFAP expression may be similar in
between transformed astrocyte and primary astrocyte cells.
Besides the inhibitory effects on basal expression, aspirin also
blocks hypoxic injury-induced GFAP up-regulation in HBAs
(Fig. 6). Considering that the inactivation of NF-κB by aspirin
treatment contributes to the reduction of GFAP mRNA and
protein levels in A172 cells, the aspirin-mediated decline in
either basal (Fig. 5) or hypoxia-induced (Fig. 6) GFAP
expression in HBAs is probably attributable, at least in part,
to the down-regulation of activating factors including NF-κB
under the treatment of aspirin in astroglial cells.
Taken together, this report is first to demonstrate that aspirin
reduces GFAP mRNA and protein levels and that NF-κB is
involved as a major target of aspirin in the regulation of GFAP
gene expression. Considering that the dramatic induction of
GFAP expression is characteristic of many neuropathological
disorders that accompany excessive reactive gliosis, as well as
Alexander disease, NF-κB could be a useful target for
preventing or treating these kinds of disorders. Further studies
are needed to elucidate the role of NF-κB-targeted drug(s)
including aspirin in in vivo systems, for example, retina reactive
gliosis or brain ischemia-induced astrogliosis.
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